Seagen is a biotechnology company that develops and commercializes therapies targeting cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, and PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Co. is developing ladiratuzumab vedotin, an antibody-drug conjugate targeting LIV-1, for patients with metastatic breast cancer and select solid tumors with high LIV-1 expression. The SGEN stock yearly return is shown above.
The yearly return on the SGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|